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the changes in business condition in Japan’s healthcare system. Methods: The 
financial statements of all 143 NHO hospitals from 2004 to 2013 were obtained to 
explore the changes in their financial conditions. We analysed them with total 
health expenditures and the revision rates of the medical fee schedule available 
from the government websites. Results: The medical fee schedule was reduced 
by 3.16% in 2006 and 0.82% in 2008, and then increased by 0.19% in 2010 and 0.004% 
in 2012. The change rate of the profit per bed in NHO hospitals was overall parallel 
to the change rate of total health expenditure except for 2010 when the change 
rates were increased in 6.9% and 3.9% respectively. The reason of the exception 
in 2010 can be associated with the transition to acute care in line with the gov-
ernment policy to promote functional differentiation of hospitals. NHO hospitals 
with more than 350 beds had continuously increased the change rate of profit 
per bed despite of the negative revisions to the medical fee schedule in 2006 and 
2008. ConClusions: Clear influence of the manipulation of the medical fee sched-
ule was observed over the profit per bed in NHO hospitals. The rate of increase in 
total health expenditure was fairly controlled by the government through the revi-
sion of the medical fee schedule.
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objeCtives: The aim of our study was to predict the future health insur-
ance expenditures according to the changes in the number of population in 
Hungary. Methods: Actual health insurance expenditure data for the base-case 
year (2013) were derived from the National Health Insurance Fund Administration 
(NHIFA) of Hungary and covered the following types of care: acute and chronic 
inpatient care, out-patient care, laboratory care, CT and MRI, drug, medical devices 
and home care. We analyzed health insurance expenditures according to age and 
gender. The prediction of future number of Hungarian population was calculated 
according to the population forecast of the Central Statistical Office of Hungary for 
2060. We applied 3 scenarios: basic, low and high number of population. Results: 
The actual health insurance expenditures of NHIFA was ö15.8 billion Hungarian 
Forint (HUF) in 2013 and the population of Hungary was 9910811 people. For the 
year 2030, health insurance expenditures were assessed 938.2 billion HUF while 
the population is predicted 9211522 people. For the year 2060, health insurance 
expenditures were assessed 908.5 billion HUF while the population is predicted 
7922289 people. Health insurance expenditures for population under 25 years was 
10.2 % of total expenditures, which decreased to 8.7 % in 2030 and 7.2 % in 2060. 
Health insurance expenditures for population over 65 years was 40.3 % of total 
expenditures, which increases to 47.0 % in 2030 and 58.9 % in 2060. ConClusions: 
Health insurance expenditures of Hungary will not increase significantly on actual 
level up to 2060. The reason behind this fact is the serious decline int he number of 
population. However, there will be a significant shift in the expenditures by decreas-
ing the proportion of population below 25 and increasing the proportion of people 
aged over 65 years.
PHP130
italian HealtHcare exPenditure trends from 2002 to 2013
D’Ausilio A1, Daniel F1, Aiello A1, Toumi M2
1Creativ Ceutical, Milano, Italy, 2Aix-Marseille University, Marseille, France
objeCtives: Italy has a tax-funded National Health System (NHS) that guar-
antees universal provision of comprehensive care. The central government 
provides policy and planning framework, defines the Essential Levels of Care 
and guarantees financial sustainability, while the regions are responsible 
for healthcare delivery and are liable for any budget deficit. Since 2005, cost-
containment and prescription appropriateness policies were developed in 
order to make regions more responsible on healthcare expenditure. The aim 
of this research was to provide an overview of national healthcare expendi-
ture trends before and after the implementation of such policies. Methods: 
Data published by the Minister for Economic and Financial Affairs were ana-
lysed to show different expenditure trends in different time periods: before 
2005 (period: 2002-2005) and after (2006-2013). Results: National healthcare 
expenditure from 2002-2013 increased by about € 30.28 billion (€ 78.97 in 2002 and 
€ 109.26 billion in 2013/year) with an average annual rate of +3.2%. Trends were 
different per period, with average annual rates of +5.4% in 2002-2005 and 
+1.3% in the period 2006-2013; +2.6% increase in the period 2006-2009 and 
-0.3% in 2010-2013. In the period 2006-2013, healthcare expenditures com-
ponents - such as healthcare professionals, general practitioners and hospi-
tal services - showed a lower average annual growth rate compared with the 
2002-2005 period. Territorial drug expenditures show a dramatic decrease 
compared to the previous period. ConClusions: Our analysis show that 
there is still room for better rationalise healthcare expenditure, however the 
greater empowerment of the regions and the policies implemented in recent 
years have improved the economic performance of the Italian healthcare 
expenditure.
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objeCtives: In Portugal, during the period 2002–2010, longevity (mean age at 
death) increased by 2.5 years. The aim of this study was to examine the effects of 
pharmaceutical innovation on the longevity from all diseases in Portugal (2002–
2010). Methods: Longitudinal disease-level data was analyzed to determine 
whether diseases for which there was greater pharmaceutical innovation - a larger 
nephrotic syndrome (1; 1.6%). ConClusions: Of the total of prescriptions, 76.1% 
were compliance with indications in national guidelines. However, unsubstantiated 
prescriptions represented a cost of around 22.0% of the total budget spent on the 
acquisition of albumin and that could have been applied in other unmet needs due 
to lack of financial resources.
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objeCtives: To assess the costs, benefits and savings of MobileCARE, an electronic 
health record (EHR) system smartphone application for clinical documentation 
developed by the United States Army and University of Miami, and implemented in a 
trauma intensive care unit (TICU). To evaluate provider perceptions of MobileCARE’s 
usability and impact on clinical workflow and productivity. Methods: A cost-
effectiveness and cost-utility analysis was conducted using hospital-level cost 
data and clinical outcomes data collected retrospectively at three time periods: 
pre-MobileCARE and two subsequent iterations of MobileCARE from 2010-2014. An 
analysis was performed of direct costs related to the mobile health intervention and 
benefits related to patient’s clinical outcomes. Qualitative interviews (n= 20) were 
conducted with providers working in the TICU and using MobileCARE. Ethnographic 
observation of clinical workflow and MobileCARE usage was conducted over the 
course of 12 days. Results: The total cost of MobileCARE was $2,655,639.67, con-
sisting of $1,943,399.47 towards platform development and a fixed, direct cost of 
implementation totaling $712,239.70. Transcription cost-savings per-provider were 
$79.25/month. Average length of stay decreased by 1.73 days, average mortality 
rate decreased by 2%, and QALDs increased by 1.8 QALD per patient over the study 
period. These clinical trends show directional improvement, although no significant 
differences were found. Overall, providers found MobileCARE acceptable, easy to 
use, positively impacted workflow, and increased their productivity. ConClusions: 
MobileCARE appears to be an affordable option for improving EHR usability, physi-
cian productivity, and clinical outcomes. The overall cost of developing MobileCARE 
is high, but consistent with similar technologies previously developed. The single-
time cost of implementation is justifiable given the ongoing cost-savings, time-
savings, indicated trends of clinical outcome benefits, and overall user acceptance 
of the system. MobileCARE is a viable option for TICU’s seeking low-cost and usable 
mobile documentation systems to enhance existing EHR system usability and effec-
tively reduce hospital transcription costs.
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objeCtives: An increase in prevalence of antimicrobial resistance among gram-
negative pathogens in complicated intra-abdominal infections (cIAI) has been noted 
recently (Sartelli et al 2013). A challenge in empiric treatment of cIAI is identifying 
initial appropriate antibiotic therapy (IAAT), which is associated with reduced length 
of stay and mortality compared with inappropriate therapy. Using local antibiogram 
data to select empiric therapy may increase the likelihood of IAAT. The objective of 
this research is to demonstrate how an economic model can assist medical decision-
making by identifying threshold differences in antibiotic resistance at which cef-
tolozane/tazobactam+metronidazole is cost-effective/cost-saving compared with 
piperacillin/tazobactam as IAAT. Methods: We used a decision analytic Monte 
Carlo simulation model (Kauf et al 2015) to compare cost and QALYs of persons 
infected with nosocomial gram-negative cIAI and treated empirically with either 
ceftolozane/tazobactam+metronidazole or piperacillin/tazobactam. We ran the 
model for baseline prevalence of resistance in the Program to Assess Ceftolozane/
Tazobactam Susceptibility (PACTS) in-vitro surveillance database. We limited thresh-
old analysis to three commonly isolated gram-negative pathogens: Escherichia coli, 
Klebsiella pneumoniae, and Pseudomonas aeruginosa. We assumed resistance for 
both drugs to be similar and then increased resistance in the piperacillin/tazobactam 
arm for all three pathogens simultaneously. Threshold differences in resistance at 
which ceftolozane/tazobactam became cost-effective were estimated. Results: 
At baseline resistance levels from PACTS, ceftolozane/tazobactam+metronidazole 
was cost-saving compared with piperacillin/tazobactam. Ceftolozane/tazobactam 
was cost-effective (cost-saving) when resistance rates for the three bacteria in the 
piperacillin/tazobactam were > 2% (7%) relative to ceftolozane/tazobactam. When 
resistance rates for E. coli alone were changed, ceftolozane/tazobactam was cost-
effective (cost-saving) at differences > 3% (13%). Results were sensitive to gram-
positive/-negative pathogen prevalence, drug/hospitalization cost. ConClusions: 
Economic models can be used to identify IAAT based on in-vitro resistance data. 
Once threshold differences in antibiotic resistance that make a comparator drug 
cost-effective are established, local antibiograms can help identify optimal IAAT.
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objeCtives: Ministry of Health, Labour and Welfare of Japan revises medical fee 
schedule biennially. The revision is performed in line with the government’s budget 
policy at national level. This study explored the influence of the manipulation of the 
medical fee schedule on National Hospital Organization (NHO) hospitals to overview 
